Suchergebnisse - "Amiot, Aurélien"

PubPharm (95)

1

Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease : A 12-month prospective cohort study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2019

von Petitdidier, N. | Tannoury, J. | de'Angelis, N. | +7

2

Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2019

von Sobhani, I. | Bergsten, E. | Couffin, S. | +10

3

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease : A GETAID Multicentre Cohort Study

enthalten in: Journal of Crohn's & colitis | 2019

von Caron, B. | Peyrin-Biroulet, L. | Pariente, B. | +21

CommentIn: J Crohns Colitis. 2019 Sep 27;13(10):1237-1238. - PMID 31560065

4

Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease : a prospective multi-centre cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2019

von Amiot, A. | Serrero, M. | Peyrin-Biroulet, L. | +97

5

Crypt- and Mucosa-Associated Core Microbiotas in Humans and Their Alteration in Colon Cancer Patients

enthalten in: mBio | 2019

von Saffarian, A. | Mulet, C. | Regnault, B. | +6

6

Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease : A multicenter retrospective study

enthalten in: Journal of the American Academy of Dermatology | 2019

von de Risi-Pugliese, T. | Seksik, P. | Bouaziz, J. | +14

7

Three‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease : a prospective multi‐centre cohort study

enthalten in: Alimentary Pharmacology & Therapeutics | 2019

von Amiot, A. | Serrero, M. | Peyrin‐Biroulet, L. | +22

8

Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2019

von Pouillon, L. | Lamoureux, A. | Pineton de Chambrun, G. | +10

CommentIn: Dig Liver Dis. 2019 Apr;51(4):609-610. - PMID 30862437

9

Expression of the human antimicrobial peptide β-defensin-1 is repressed by the EGFR-ERK-MYC axis in colonic epithelial cells

enthalten in: Scientific reports | 2018

von Bonamy, C. | Sechet, E. | Amiot, A. | +5

10

Risk of serious infection in healthcare workers with inflammatory bowel disease : a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)

enthalten in: Alimentary pharmacology & therapeutics | 2018

von Gagnière, C. | Bourrier, A. | Seksik, P. | +55

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]